Brainstorm Cell Therapeutics Files 8-K on Officer Changes & Shareholder Votes
Ticker: BCLI · Form: 8-K · Filed: Jun 25, 2025 · CIK: 1137883
| Field | Detail |
|---|---|
| Company | Brainstorm Cell Therapeutics Inc. (BCLI) |
| Form Type | 8-K |
| Filed Date | Jun 25, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, governance, shareholder-vote
Related Tickers: BCLI
TL;DR
Brainstorm Cell Therapeutics (BCLI) filed an 8-K covering leadership changes, director elections, and shareholder votes.
AI Summary
On June 25, 2025, Brainstorm Cell Therapeutics Inc. filed an 8-K report detailing several key events. The filing includes information regarding the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for these officers. Additionally, the report covers the submission of matters to a vote of security holders and financial statements and exhibits.
Why It Matters
This 8-K filing signals potential shifts in the company's leadership and governance structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with shareholder votes, can indicate internal restructuring or strategic shifts that may carry inherent risks.
Key Players & Entities
- Brainstorm Cell Therapeutics Inc. (company) — Registrant
- June 25, 2025 (date) — Date of earliest event reported
FAQ
What specific officer positions were affected by the departures or appointments?
The filing indicates changes in directors or certain officers and the appointment of certain officers, but does not specify the exact positions in the provided text.
Were there any specific matters submitted to a vote of security holders?
Yes, the filing states that matters were submitted to a vote of security holders, but the specific matters are not detailed in this excerpt.
What is the SIC code for Brainstorm Cell Therapeutics Inc.?
The Standard Industrial Classification (SIC) code for Brainstorm Cell Therapeutics Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
When is Brainstorm Cell Therapeutics Inc.'s fiscal year end?
Brainstorm Cell Therapeutics Inc.'s fiscal year ends on December 31.
What are the previous names of Brainstorm Cell Therapeutics Inc.?
Previous names for Brainstorm Cell Therapeutics Inc. include Golden Hand Resources Inc. (name change date: 20030827) and Wizbang Technologies Inc. (name change date: 20010409).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 25, 2025 regarding BRAINSTORM CELL THERAPEUTICS INC. (BCLI).